Organizations Filed Purposes:
TargetCancer Foundation promotes the development of lifesaving treatment protocols for rare cancers. TargetCancer Foundation directly supports initiatives at the forefront of cancer treatment by funding innovative research, fostering collaborations, and raising awareness among scientists, clinicians, and patients.
Support for research into the causes and treatments of rare cancers.
The specific purposes of the Organization are to raise awareness of and support for research into the rare cancers, and to directly support patients facing rare cancers. This was accomplished in the fiscal year by providing new research grants and through other programs. In 2019, TargetCancer Foundation provided $90,000 to support Dr. Nabeel Bardeesy's cholangiocarcinoma research at the Massachusetts General Hospital Cancer Center, representing the first payment of a $240,000 grant. This support marked the tenth year of an ongoing commitment totaling over $1 million to create a comprehensive cholangiocarcinoma research program at the Bardeesy lab, with a specific focus on the development of a cholangiocarcinoma cell line repository. With this grant, the repository will be fully moved into the public domain for the first time, enabling access to these critical tools for researchers around the world. In addition, on November 12-13, 2019, TargetCancer Foundation held the 3rd Think Tank on Advancing Gastroesophageal Cancer Research, a 2-day scientific meeting in Boston that united over 100 leading clinicians and scientists. This unique meeting is specifically designed to promote collaboration, information-sharing and idea generation in an effort to define research priorities, foster new collaborative efforts across institutions, and ultimately propel the field of gastroesophageal cancer research forward.In 2019, TargetCancer Foundation also made a significant investment in the development of a new rare cancer clinical trial called TCF-001 TRACK (Target Rare Cancer Knowledge). TRACK is a 400-patient clinical trial studying genomics and precision medicine in rare cancers. TRACK is developed, sponsored and managed by TargetCancer Foundation, and while this innovative initiative would launch in 2020, the development phase of the study took place throughout 2019.
Executives Listed on Filing
Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing
| Name | Title | Hours Per Week | Total Salary |
|---|
| James M Palma | Executive Director | 50 | $98,287 |
| Kristen Palma | President/Director | 20 | $18,333 |
| Charles Cheever | Treasurer/Director | 1 | $0 |
| Jennifer Levin Carter Md | Director | 1 | $0 |
| Colin Carey | Director | 1 | $0 |
| Janet Fine Ms | Director | 1 | $0 |
| Samuel Davenport | Director | 1 | $0 |
| Mary Pat Lancelotta | Director | 1 | $0 |
| Cj Chapman | Director | 1 | $0 |
| Alicemarie Hand | Director (end March 2019) | 1 | $0 |
| Kristen Schuler Scammon | Director | 1 | $0 |
Data for this page was sourced from XML published by IRS (
public 990 form dataset) from:
https://s3.amazonaws.com/irs-form-990/202033509349300208_public.xml